Assessing Progress in Reducing the At- Risk Population after 13 Years of the Global Programme to Eliminate Lymphatic Filariasis

被引:27
作者
Hooper, Pamela J. [1 ]
Chu, Brian K. [1 ]
Mikhailov, Alexei [2 ]
Ottesen, Eric A. [1 ,3 ]
Bradley, Mark [4 ]
机构
[1] Task Force Global Hlth, Neglected Trop Dis Support Ctr, Decatur, GA 30030 USA
[2] WHO, Control Neglected Trop Dis, CH-1211 Geneva, Switzerland
[3] RTI Int, ENVISION Project, Washington, DC USA
[4] GlaxoSmithKline, Global Hlth Programs, London, England
来源
PLOS NEGLECTED TROPICAL DISEASES | 2014年 / 8卷 / 11期
基金
比尔及梅琳达.盖茨基金会;
关键词
WUCHERERIA-BANCROFTI INFECTION; MASS TREATMENT; DIETHYLCARBAMAZINE; ALBENDAZOLE; IVERMECTIN; PREVALENCE;
D O I
10.1371/journal.pntd.0003333
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: In 1997, the World Health Assembly adopted Resolution 50.29, committing to the elimination of lymphatic filariasis (LF) as a public health problem, subsequently targeted for 2020. The initial estimates were that 1.2 billion people were at-risk for LF infection globally. Now, 13 years after the Global Programme to Eliminate Lymphatic Filariasis (GPELF) began implementing mass drug administration (MDA) against LF in 2000-during which over 4.4 billion treatments have been distributed in 56 endemic countries-it is most appropriate to estimate the impact that the MDA has had on reducing the population at risk of LF. Methodology/Principal Findings: To assess GPELF progress in reducing the population at-risk for LF, we developed a model based on defining reductions in risk of infection among cohorts of treated populations following each round of MDA. The model estimates that the number of people currently at risk of infection decreased by 46% to 789 million through 2012. Conclusions/Significance: Important progress has been made in the global efforts to eliminate LF, but significant scale-up is required over the next 8 years to reach the 2020 elimination goal.
引用
收藏
页数:7
相关论文
共 19 条
  • [1] [Anonymous], 2013, Wkly Epidemiol Rec, V88, P389
  • [2] [Anonymous], 2011, MON EP ASS MASS DRUG
  • [3] Mass treatment to eliminate filariasis in Papua New Guinea
    Bockarie, MJ
    Tisch, DJ
    Kastens, W
    Alexander, NDE
    Dimber, Z
    Bockarie, F
    Ibam, E
    Alpers, MP
    Kazura, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (23) : 1841 - 1848
  • [4] Bockarie Moses J., 2000, Papua New Guinea Medical Journal, V43, P172
  • [5] The Economic Benefits Resulting from the First 8 Years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007)
    Chu, Brian K.
    Hooper, Pamela J.
    Bradley, Mark H.
    McFarland, Deborah A.
    Ottesen, Eric A.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2010, 4 (06):
  • [6] Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India
    Das, PK
    Ramaiah, KD
    Vanamail, P
    Pani, SP
    Yuvaraj, J
    Balarajan, K
    Bundy, DAP
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (03) : 336 - 341
  • [7] The history of the elimination of lymphatic filariasis in China
    Sun De-jian
    Deng Xu-li
    Duan Ji-hui
    [J]. INFECTIOUS DISEASES OF POVERTY, 2013, 2 : 1 - 9
  • [8] Endpoints for lymphatic filariasis programs
    Grady, Caroline A.
    de Rochars, Madsen Beau
    Direny, Abdel N.
    Orelus, Jean Nicolas
    Wendt, Joyanna
    Radday, Jeanne
    Mathieu, Els
    Roberts, Jacquelin M.
    Streit, Thomas G.
    Addiss, David G.
    Lammie, Patrick J.
    [J]. EMERGING INFECTIOUS DISEASES, 2007, 13 (04) : 608 - 610
  • [9] KIMURA E, 1992, B WORLD HEALTH ORGAN, V70, P769
  • [10] Re-assessing the global prevalence and distribution of lymphatic filariasis
    Michael, E
    Bundy, DAP
    Grenfell, BT
    [J]. PARASITOLOGY, 1996, 112 : 409 - 428